Northern Trust Corp boosted its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 14.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,202,941 shares of the medical instruments supplier’s stock after buying an additional 155,951 shares during the period. Northern Trust Corp owned about 3.28% of AngioDynamics worth $19,500,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently bought and sold shares of ANGO. State of Alaska Department of Revenue raised its holdings in AngioDynamics by 91.7% during the 2nd quarter. State of Alaska Department of Revenue now owns 6,768 shares of the medical instruments supplier’s stock worth $109,000 after buying an additional 3,238 shares during the period. Teachers Retirement System of The State of Kentucky grew its stake in AngioDynamics by 77.5% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 7,100 shares of the medical instruments supplier’s stock valued at $123,000 after acquiring an additional 3,100 shares in the last quarter. Municipal Employees Retirement System of Michigan grew its stake in AngioDynamics by 3.0% during the 1st quarter. Municipal Employees Retirement System of Michigan now owns 7,200 shares of the medical instruments supplier’s stock valued at $125,000 after acquiring an additional 210 shares in the last quarter. Mason Street Advisors LLC grew its stake in AngioDynamics by 8.5% during the 1st quarter. Mason Street Advisors LLC now owns 7,470 shares of the medical instruments supplier’s stock valued at $130,000 after acquiring an additional 584 shares in the last quarter. Finally, Acrospire Investment Management LLC grew its stake in AngioDynamics by 3.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 8,915 shares of the medical instruments supplier’s stock valued at $145,000 after acquiring an additional 317 shares in the last quarter. Hedge funds and other institutional investors own 96.05% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/11/11/northern-trust-corp-acquires-155951-shares-of-angiodynamics-inc-ango.html.
Shares of AngioDynamics, Inc. (ANGO) traded down $0.30 during midday trading on Friday, hitting $16.70. The company had a trading volume of 132,300 shares, compared to its average volume of 240,808. The company has a market cap of $624.17, a PE ratio of 24.64, a price-to-earnings-growth ratio of 1.74 and a beta of 1.05. AngioDynamics, Inc. has a 1-year low of $14.80 and a 1-year high of $18.85. The company has a current ratio of 2.34, a quick ratio of 1.48 and a debt-to-equity ratio of 0.17.
AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Thursday, September 28th. The medical instruments supplier reported $0.12 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.16 by ($0.04). The firm had revenue of $85.40 million during the quarter, compared to the consensus estimate of $86.12 million. AngioDynamics had a net margin of 1.64% and a return on equity of 4.83%. The company’s quarterly revenue was down 3.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.17 EPS. analysts predict that AngioDynamics, Inc. will post 0.65 EPS for the current fiscal year.
Several equities analysts have weighed in on ANGO shares. Barclays PLC lowered their target price on AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 19th. Zacks Investment Research cut AngioDynamics from a “hold” rating to a “sell” rating in a research note on Thursday, July 20th. Canaccord Genuity reaffirmed a “hold” rating and set a $17.00 target price on shares of AngioDynamics in a research note on Tuesday, July 18th. KeyCorp reaffirmed a “hold” rating on shares of AngioDynamics in a research note on Friday, August 25th. Finally, BidaskClub raised AngioDynamics from a “sell” rating to a “hold” rating in a research note on Saturday, August 19th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $18.60.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.